531-09-9 Usage
Uses
Used in Allergy Treatment:
Bromopyramine is used as an antihistamine for relieving symptoms of allergies, such as sneezing, runny nose, and itchy/watery eyes. It achieves this by blocking the action of histamine, a substance in the body that causes allergic symptoms.
Used in Allergic Rhinitis Treatment:
Bromopyramine is used as a medication for treating allergic rhinitis, a condition characterized by inflammation of the nasal passages due to allergens. It helps alleviate symptoms such as sneezing, runny nose, and itchy/watery eyes.
Used in Other Allergic Conditions:
Bromopyramine is used in combination with other medications for treating various other allergic conditions, providing relief from symptoms associated with these conditions.
It is important to follow the dosing instructions provided by a healthcare professional and to avoid taking bromopyramine with alcohol or other medications that may cause drowsiness. Common side effects of bromopyramine may include drowsiness, dizziness, dry mouth, and blurred vision.
Check Digit Verification of cas no
The CAS Registry Mumber 531-09-9 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 5,3 and 1 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 531-09:
(5*5)+(4*3)+(3*1)+(2*0)+(1*9)=49
49 % 10 = 9
So 531-09-9 is a valid CAS Registry Number.
531-09-9Relevant academic research and scientific papers
Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction
Gogate, Priyanka N.,Ethirajan, Manivannan,Kurenova, Elena V.,Magis, Andrew T.,Pandey, Ravindra K.,Cance, William G.
, p. 154 - 156 (2014/05/20)
Focal adhesion kinase (FAK) and vascular endothelial growth factor receptor 3 (VEGFR3) are tyrosine kinases, which function as key modulators of survival and metastasis signals in cancer cells. Previously, we reported that small molecule chlorpyramine hydrochloride (C4) specifically targets the interaction between FAK and VEGFR3 and exhibits anti-tumor efficacy. In this study, we designed and synthesized a series of 1 (C4) analogs on the basis of structure activity relationship and molecular modeling. The resulting new compounds were evaluated for their binding to the FAT domain of FAK and anti-cancer activity. Amongst all tested analogs, compound 29 augmented anti-proliferative activity in multiple cancer cell lines with stronger binding to the FAT domain of FAK and disrupted the FAK-VEGFR3 interaction. In conclusion, we hope that this work will contribute to further studies of more potent and selective FAK-VEGFR3 protein-protein interaction inhibitors.
